Form 8-K - Current report:
SEC Accession No. 0001714899-21-000066
Filing Date
2021-07-26
Accepted
2021-07-26 08:29:59
Documents
14
Period of Report
2021-07-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20210725.htm   iXBRL 8-K 40715
2 EX-99.1 ex991pressrelease7262021.htm EX-99.1 29029
6 denali_txlogox01a.jpg GRAPHIC 65449
  Complete submission text file 0001714899-21-000066.txt   301903

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20210725.xsd EX-101.SCH 1932
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20210725_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20210725_pre.xml EX-101.PRE 12528
7 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20210725_htm.xml XML 10835
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 211112532
SIC: 2836 Biological Products, (No Diagnostic Substances)